Stemina Biomarker Discovery
Stemina Biomarker Discovery, based in Madison, US, enhances drug safety and human health through molecular biomarkers.
Founded
2006Stemina Biomarker Discovery, based in Madison, US, enhances drug safety and human health through molecular biomarkers.
Stemina Biomarker Discovery, founded in Madison, US, is dedicated to enhancing drug safety and human health through the development and commercialization of molecular biomarkers. The company's core mission is to leverage cutting-edge biomarker technology to predict and prevent adverse drug reactions and improve patient outcomes. Stemina offers products such as Cardio quick Predict™ and devTOX quick Predict™, which are designed to assess the safety of pharmaceutical compounds. Their market focus includes pharmaceutical companies, regulatory agencies, and healthcare providers.
Notable figures associated with Stemina include its Board of Directors and a distinguished Scientific Advisory Board comprising experts in biomarker research and drug safety. The company has achieved significant milestones, including the successful commercialization of its predictive toxicology assays and securing partnerships with leading pharmaceutical firms. Stemina's impact is evident in its contributions to safer drug development processes and its role in advancing personalized medicine.
Companies similar to Stemina Biomarker Discovery include Stem Pharm, Pbs-Bio, MeCo Diagnostics and Denovo Biopharma.
Stemina Biomarker Discovery was founded in 2006.
Stemina Biomarker Discovery's headquarters is located in Madison, WI, US.
Stemina Biomarker Discovery's most recent funding round was for $3.1M (USD) in January 2017.
As of Jan 1, 2017, Stemina Biomarker Discovery has disclosed funding of $16.4M (USD). Undisclosed round amounts are excluded.
Stemina Biomarker Discovery has 35 employees as of Feb 5, 2024.
